UNSPSC 51263137: Xipranolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C23H33NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZJI41P5WMH, chemically known as 2-propanol, 1-(di-2,6-xylylmethoxy)-3-(isopropylamino)- but generally known as xipranolol, which bears US NIH Compound Identifier 65692. European Medicines Agency schedules Xipranolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00117MIG.

UNSPSC 51263137 Xipranolol is a Commodity code covering pharmaceutical products, though the recent state and local opportunities tagged under it reveal a substantial mismatch between the code's nominal scope and actual procurement activity. The two opportunities on record — one from Seminole County, Florida and one from the Texas Health and Human Services Commission — solicit naloxone and safe drug deactivation systems (Florida) and direct-to-manufacturer prescription program capabilities (Texas), neither of which align with xipranolol specifically. The code shows minimal relevant recent activity, with no direct procurement of xipranolol documented in state or local competitive solicitations during the review period.

Seminole County released IFB 60459723LAS on June 30, 2026 (response deadline July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through electronic bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, seeking information about direct contracting capacity, negotiated net pricing models, and value-based agreements. Neither opportunity relates to xipranolol procurement or represents the commodity code's intended scope.